What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: IMARC | PRODUCT CODE: 1378847

PUBLISHER: IMARC | PRODUCT CODE: 1378847

Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

PUBLISHED: November 2, 2023

PAGES: 149 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

The global pharmerging market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 12.2% during 2022-2028.

Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market report, along with forecasts at the global and country level from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Pharmaceuticals

Patented Prescription Drugs

Generic Prescription Drugs

OTC Drugs

Healthcare

Medical Devices

Clinical Diagnosis

Others

Breakup by Indication:

Lifestyle Diseases

Cancer and Autoimmune Diseases

Infectious Diseases

Others

Breakup by Distribution Channel:

Hospitals

Retail Pharmacies

Online Stores

Others

Breakup by Country:

Tier I

China

Tier II

India

Brazil

Russia

South Africa

Tier III

Argentina

Mexico

Poland

Ukraine

Turkey

Saudi Arabia

Egypt

Algeria

Nigeria

Thailand

Indonesia

Pakistan

Others

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

How has the global pharmerging market performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the impact of COVID-19 on the global pharmerging market?
What is the breakup of the market based on the product?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the market?
What is the structure of the global pharmerging market and who are the key players?
What is the degree of competition in the market?

Product Code: SR112023A3441

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Pharmerging Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Pharmaceutical
- 6.1.1 Market Trends
- 6.1.2 Major Types
  - 6.1.2.1 Patented Prescription Drugs
  - 6.1.2.2 Generic Prescription Drugs
  - 6.1.2.3 OTC Drugs
- 6.1.3 Market Forecast
6.2 Healthcare
- 6.2.1 Market Trends
- 6.2.2 Major Types
  - 6.2.2.1 Medical Devices
  - 6.2.2.2 Clinical Diagnosis
  - 6.2.2.3 Others
- 6.2.3 Market Forecast

7 Market Breakup by Indication

7.1 Lifestyle Diseases
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Cancer and Autoimmune Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Infectious Diseases
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Country

9.1 Tier I
- 9.1.1 China
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
9.2 Tier II
- 9.2.1 India
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Brazil
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 Russia
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Africa
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
9.3 Tier III
- 9.3.1 Argentina
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 Mexico
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 Poland
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Ukraine
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Turkey
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Saudi Arabia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Egypt
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
- 9.3.8 Algeria
  - 9.3.8.1 Market Trends
  - 9.3.8.2 Market Forecast
- 9.3.9 Nigeria
  - 9.3.9.1 Market Trends
  - 9.3.9.2 Market Forecast
- 9.3.10 Thailand
  - 9.3.10.1 Market Trends
  - 9.3.10.2 Market Forecast
- 9.3.11 Indonesia
  - 9.3.11.1 Market Trends
  - 9.3.11.2 Market Forecast
- 9.3.12 Pakistan
  - 9.3.12.1 Market Trends
  - 9.3.12.2 Market Forecast
- 9.3.13 Others
  - 9.3.13.1 Market Trends
  - 9.3.13.2 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Sanofi S.A.
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Pfizer Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 AstraZeneca Plc.
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 GlaxoSmithKline Plc.
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 Financials
  - 13.3.5.4 SWOT Analysis
- 13.3.6 Eli Lilly and Company
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 Johnson & Johnson
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 Abbott Laboratories
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
  - 13.3.8.4 SWOT Analysis
- 13.3.9 Novartis AG
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
  - 13.3.9.3 Financials
  - 13.3.9.4 SWOT Analysis
- 13.3.10 Teva Pharmaceutical Limited
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financial
  - 13.3.10.4 SWOT Analysis

Product Code: SR112023A3441

List of Figures

Figure 1: Global: Pharmerging Market: Major Drivers and Challenges
Figure 2: Global: Pharmerging Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Pharmerging Market: Breakup by Product (in %), 2022
Figure 4: Global: Pharmerging Market: Breakup by Indication (in %), 2022
Figure 5: Global: Pharmerging Market: Breakup by Distribution Channel (in %), 2022
Figure 6: Global: Pharmerging Market: Breakup by Country (in %), 2022
Figure 7: Global: Pharmerging Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 8: Global: Pharmerging (Pharmaceuticals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Pharmerging (Pharmaceuticals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Pharmerging (Healthcare) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Pharmerging (Healthcare) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Pharmerging (Lifestyle Diseases) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Pharmerging (Lifestyle Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Pharmerging (Cancer and Autoimmune Diseases) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Pharmerging (Cancer and Autoimmune Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Pharmerging (Infectious Diseases) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Pharmerging (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Pharmerging (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Pharmerging (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Pharmerging (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Pharmerging (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Pharmerging (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Pharmerging (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Pharmerging (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Pharmerging (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Pharmerging (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Pharmerging (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Tier I: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Tier I: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: China: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: China: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Tier II: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Tier II: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: India: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: India: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Brazil: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Brazil: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Russia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Russia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: South Africa: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: South Africa: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Tier III: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Tier III: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Argentina: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Argentina: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Mexico: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Mexico: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Poland: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Poland: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Ukraine: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Ukraine: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Turkey: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Turkey: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Saudi Arabia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Saudi Arabia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Egypt: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Egypt: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Algeria: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Algeria: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Nigeria: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Nigeria: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Thailand: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Thailand: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Indonesia: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Indonesia: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Pakistan: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Pakistan: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Others: Pharmerging Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Others: Pharmerging Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Global: Pharmerging Industry: SWOT Analysis
Figure 71: Global: Pharmerging Industry: Value Chain Analysis
Figure 72: Global: Pharmerging Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Pharmerging Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Pharmerging Market Forecast: Breakup by Product (in Million US$), 2023-2028
Table 3: Global: Pharmerging Market Forecast: Breakup by Indication (in Million US$), 2023-2028
Table 4: Global: Pharmerging Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 5: Global: Pharmerging Market Forecast: Breakup by Country (in Million US$), 2023-2028
Table 6: Global: Pharmerging Market: Competitive Structure
Table 7: Global: Pharmerging Market: Key Players